We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma.
- Authors
Cornelison, Robert; Marrah, Laine; Horter, Drew; Lynch, Sarah; Li, Hui
- Abstract
Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope.
- Subjects
GLIOBLASTOMA multiforme; MICROFILAMENT proteins; CYTOREDUCTIVE surgery; RADIOTHERAPY; TEMOZOLOMIDE
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 24, p13635
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms222413635